FDA Adverse Event Injury Summary report: N

PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 2231659 · Received September 1, 2011

Report

Report Number
2024168-2011-06090
Event Type
Injury
Date Received
September 1, 2011
Date of Event
February 11, 2011
Report Date
August 10, 2011
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P070015
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. YOU ARE RECEIVING THIS MDR REPORT FROM ABBOTT VASCULAR BECAUSE BOSTON SCIENTIFIC CORPORATION DISTRIBUTES PROMUS AS ITS OWN BRAND LABELING OF ABBOTT VASCULARS DRUG ELUTING STENT IN THE US. THERE WAS NO REPORTED PRODUCT DEFICIENCY AND THE PRODUCT WAS NOT RETURNED. ANGINA AND RESTENOSIS ARE KNOWN ADVERSE EVENTS AS LISTED IN THE PROMUS INSTRUCTIONS FOR USE. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS AND THE RELATIONSHIP, IF ANY, TO THE DEVICE COULD NOT BE DETERMINED; THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURE, DESIGN OR LABELING.

Description of Event or Problem · 1

IT WAS REPORTED THAT APPROXIMATELY NINETEEN MONTHS POST PROMUS STENTING PROCEDURE IN THE FIRST OBTUSE MARGINAL ARTERY WITH ONE 2.5 X 18 MM STENT, THE PATIENT WAS HOSPITALIZED WITH ANGINA PECTORIS. ON (B)(6) 2011, THE PATIENT UNDERWENT PERCUTANEOUS CORONARY REVASCULARIZATION BALLOON ANGIOPLASTY IN THE INDEX TARGET LESION AND IN THE PROXIMAL LEFT CIRCUMFLEX, NON-TARGET VESSEL. THE PATIENT'S CONDITION RESOLVED AND THE PATIENT WAS DISCHARGED ON (B)(6) 2011. THERE WAS NO REPORTED ADVERSE PATIENT SEQUELA. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 8111261

Patients

Seq Age Sex Outcome Treatment
1 56 YR Hospitalization| R